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Hepatic stellate cell (HSC) proliferation is a key event in liver fibrosis and, 
therefore, pharmacological intervention with antiproliferative drugs may result in 
antifibrotic effects. In this paper, the antiproliferative effect of three cytostatic 
drugs is tested in cultured rat HSC. Subsequently, the antifibrotic potential of the 
most potent drug was evaluated in vivo. As a strategy to overcome drug-related 
toxicity, we additionally studied how to deliver this drug specifically to HSC by 
conjugating it to the HSC-selective drug carrier mannose-6-phosphate-modified 
human serum albumin (M6PHSA). We investigated the effect of cisplatin, 
chlorambucil and doxorubicin on BrdU-incorporation in cultured HSC, and found 
DOX to be the most potent drug. Treatment of bile duct-ligated (BDL) rats with 
daily i.v. injections of 0.35 mg/kg DOX from day 3 to day 10 after BDL, reduced 
α-smooth muscle actin-stained area in liver sections from 8.5±0.8 to 5.1±0.9% (P< 
0.01) and collagen-stained area from 13.1±1.3 to 8.9±1.5% (P<0.05). DOX was 
coupled to M6PHSA and the organ distribution of this construct (M6PHSA-DOX) 
was investigated. Twenty minutes after i.v. administration, 50±6% of the dose was 
present in the livers and co-localization of M6PHSA-DOX with HSC-markers was 
observed. Additionally, in vitro studies showed selective binding of M6PHSA-
DOX to activated HSC. Moreover, M6PHSA-DOX strongly attenuated HSC 
proliferation in vitro, indicating that active drug is released after uptake of the 
conjugate. In conclusion, DOX inhibits liver fibrosis in BDL rats and HSC-
selective targeting of this drug is possible. This may offer perspectives for the 
application of antiproliferative drugs for antifibrotic purposes. 
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INTRODUCTION 
Liver fibrosis is the common response to chronic liver injury. The activated 
hepatic stellate cell (HSC) is generally considered as the key cell that is responsible 
for the excessive collagen deposition during this disease. New antifibrotic 
strategies therefore mainly focus on the discovery of drugs that inhibit stellate cell 
functioning (1-7). 
Since HSC proliferation is the hallmark of liver fibrosis, the question emerges 
what would happen if HSC proliferation is inhibited during the fibrotic process. 
Cytostatic drugs are among the most potent inhibitors of cell proliferation and 
effects of these drugs on wound healing are well known (8). However, to our 
knowledge no attempts to test cytostatic drugs in fibrotic animals have been made. 
Obviously, an important concern when using such drugs is the occurrence of 
serious side effects in non-hepatic tissues. Even within the liver, treatment with 
antiproliferative drugs may result in unwanted effects. For instance, inhibition of 
hepatocyte proliferation may be detrimental to the renewal of functional liver 
parenchyma, a crucial process in the fibrotic liver (9).  
In recent years, HSC-selective drug carriers have become available, which 
allow drugs to be delivered to HSC with increased specificity (10-12). Conjugating 
very potent inhibitors of cell proliferation to the HSC-selective drug carrier 
mannose-6-phosphate-modified human serum albumin (M6PHSA) has therefore 
now become an option. M6PHSA has been shown to accumulate in HSC in vivo 
via binding to mannose-6-phosphate/insulin-like growth factor-II receptors, which 
are upregulated on the cell surface of activated HSC (10;13;14). Ligands bound to 
the receptor are subject to receptor-mediated endocytosis and are routed to the 
acidic lysosomal compartment, where degradation of the construct and subsequent 
release of the coupled drug may take place (15;16). If cytostatic drugs can be 




systemic side effects and may improve the applicability of potent antiproliferative 
agents for antifibrotic purposes, in the future. 
The present study first evaluates the antiproliferative effect of three cytostatic 
drugs in culture-activated rat HSC. Subsequently, the most promising drug from 
these experiments, doxorubicin (DOX), was tested in a rat experimental model for 
liver fibrosis, in order to provide better rationale for its use as an antifibrotic drug. 
Finally, we use in vitro and in vivo techniques to investigate whether DOX can be 
selectively delivered to the HSC in a pharmacologically active form by coupling it 
to M6PHSA.  
MATERIALS AND METHODS 
HSC isolation 
HSC were isolated from the livers of male Wistar rats (> 400 g, Harlan, Horst, 
The Netherlands) according to the method of Geerts et al. (17). After isolation, 
HSC were cultured at 37 ºC in a 95% air, 5% CO2 atmosphere in Dulbecco’s 
Modified Eagles Medium with glutamax-1 (Gibco, Breda, The Netherlands), 
supplemented with 10% FCS (Biowithaker), 100 U/ml penicillin (Sigma, 
Gillingham, UK) and 100 µg/ml streptomycin (Sigma). The purity of the HSC 
culture was assessed after 9 days of culture in the described medium, during which 
HSC activation spontaneously occurs. In these cultures, always more than 95% of 
the cells were positive for the activated HSC marker α-smooth muscle actin (α-
sma), as assessed by immunohistochemical staining and cell counting. 
Effect of drugs on HSC proliferation in vitro 
After 9 days in culture, when HSC displayed an activated phenotype, cells were 
seeded in 24-wells plates at a density of 30,000 cells per well. Cells were incubated 
with various concentrations of chlorambucil (Sigma), doxorubicin (Pfizer, Capelle 
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aan den IJssel, The Netherlands) or cisplatin (Sigma) in the presence of 10% FCS, 
50 ng/ml Platelet Derived Growth Factor-BB (PDGF-BB) and 10 µM 5-bromo-2’-
deoxyuridine for 24h (BrdU, Sigma) to allow detection of proliferating cells by 
immunohistochemistry. BrdU-incorporation was subsequently quantified by cell 
counting as described previously (18). 
Antifibrotic potential of doxorubicin in BDL rats 
Experimental animals 
Male Wistar rats of 220-240g were used. Animals had free access to tap water 
and standard lab chow (Harlan, Horst, The Netherlands). All experiments were 
approved by the local committee for care and use of laboratory animals and were 
performed according to strict governmental and international guidelines for the use 
of experimental animals. Liver fibrosis was induced by ligation of the common bile 
duct as described previously (10). 
Experimental setup 
Ten animals were subjected to bile duct ligation under isoflurane/N2O/O2 
anaesthesia at day 0 of the protocol. On day 3, the animals were randomly divided 
into two groups and were treated with either PBS (n=5) or DOX (n=5) at a dose of 
0.35 mg/kg/day. A total of 7 i.v. injections was given, starting on day 3 of the 
protocol and the animals were sacrificed 24 hours after the last injection on day 10. 
Three additional rats were not submitted to bile duct ligation and served as control 
group.  
Number of activated HSC and the extent of liver fibrosis 
The number of activated HSC in the liver was assessed by staining for α-sma 
(Sigma, Gillingham, UK) on 4 µm cryostat sections, according to standard indirect 
immunohistochemical techniques. To study the extent of fibrosis, cryostat sections 
of livers were stained for collagen type III (Southern Biotechnology, Birmingham, 
UK). Also, formalin-fixed paraffin-embedded tissue samples were stained with 
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picrosirius-red dye to stain all collagens (Sigma). Microphotographs of both 
stainings were taken at an original magnification of 4x10. The fibrotic area per 
liver section was quantified by morphometric analysis of the sections using the 
Image J software package (NIH, Bethesda, ML, USA). Secondary to the 
antifibrotic effects, also adverse effects were assessed. General toxicity was 
monitored by analysis of body weight (BW), whereas intrahepatic toxicity of DOX 
towards liver cells was examined by analysis of serum AST, ALT, AP and γ-GT 
levels. Inflammatory cell influx in the livers was assessed by diaminobenzidine 
(DAB) staining as described previously, as well as by evaluation of 
haematoxylin/eosin-stained liver sections (18;19). To evaluate the effect of DOX 
on the bile duct epithelial cell proliferation, staining with a monoclonal antibody 
raised against cytokeratin 7 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) 
was performed, according to standard indirect immunohistochemical techniques. 
Synthesis and characterization of M6PHSA-DOX 
M6PHSA was synthesized as described by Beljaars et al. (10). DOX was 
coupled to this drug carrier via cisaconitic acid according to the method of Shen 
and Ryser, covalently linking the drug and the carrier via an acid-sensitive spacer, 
which allows drug release within the acidic lysosomal compartment of cells (20). 
M6PHSA-DOX was subsequently purified by dialysis against PBS and size-
exclusion chromatography on a HiLoad 16/60 Superdex 200 column (Amersham 
Biosciences, Uppsala, Sweden). After further dialysis against water, the product 
was lyophilized and stored at –20 °C until use. 
Chemical characterization M6PHSA-DOX 
The total amount of coupled DOX was assessed by spectrophotometric analysis 
(21;22). In brief, the conjugate was dissolved in PBS in a concentration of 1 
mg/ml. The absorption at 480 nm was measured and the total amount of DOX in 
the preparation was calculated from a calibration curve. The amount of free drug 
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was subsequently assessed on an HPLC system fitted with a pump (model 510, 
Waters, Milford, MA), a Thermoquest 250 x 4.6 mm 5 µm Hypersil BDS C8 
column (Thermo Electron Corporation, Waltham, MA) and a UV detector (model 
441, Waters) at 254 nm. A solution of 6.7 g trisodiumcitrate in 760 ml water and 
240 ml acetonitril (pH adjusted to 4 with formic acid) was used for elution at a 
flow of 1 ml/min. Monomeric protein content was analyzed by standard SDS-
PAGE techniques, using a 10% polyacrylamide gel. The net negative charge of 
M6PHSA-DOX and control proteins was assessed by anion exchange 
chromatography on a mono Q column as described previously (10). 
In vivo distribution of DOX and M6PHSA-DOX 
In vivo organ distribution of 125I-labeled M6PHSA-DOX 
One week after bile duct ligation (BDL), animals were injected i.v. with a 
tracer dose of 125I-labeled M6PHSA-DOX under O2/N2O/Isoflurane anaesthesia. 
Twenty minutes after injection, blood samples were taken by heart puncture (5-10 
ml), and the animals were subsequently sacrificed by bleeding after severing the 
aorta. Organs were harvested and processed as described before. All urine present 
in the bladder was collected in order to measure the amount of radioactivity that 
was excreted into the urine. The organ-associated radioactivity was expressed per 
whole organ, and was corrected for blood-derived radioactivity. The latter was 
calculated from the radioactivity present in each organ of BDL rats that were 
injected with 125I-labeled HSA, which is known to remain in the blood. The 
percentage of the dose of M6PHSA-DOX in blood was calculated from the amount 
of radioactivity in the 5-10 ml blood sample, by extrapolation to the corresponding 
value for the total blood volume in rats (60 ml/kg) (10). 
Localization of the untargeted and targeted drug 
To investigate the distribution of DOX, 20 minutes after i.v. injection of the 
uncoupled form (2mg/kg), after injection of M6PHSA-DOX (30 mg/kg, which 
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contains an amount of 2 mg/kg DOX), or after injection of PBS, the animals were 
sacrificed and 4 µm cryostat sections of liver, kidney and heart were made. These 
sections were examined by fluorescence microscopy, without embedding the 
sections in a mounting medium first, since this may corrupt the original 
localization of DOX.  Microphotographs were taken with an Olympus C5050 zoom 
digital camera and were converted to blue-scale images, so the localization of DOX 
could be better discerned. 
Cellular localization of M6PHSA-DOX 
One week after BDL, animals were injected i.v. with 30 mg/kg M6PHSA-
DOX. After 20 minutes the animals were sacrificed and tissues were excised and 
frozen in isopentane at -80 °C. Cryostat sections (4 µm) of liver, heart and kidney 
were acetone-fixed and stained for the presence of the conjugate with an antibody 
directed against human serum albumin (HSA, Cappel, Zoetermeer, The 
Netherlands). In addition, we investigated whether there was co-localization of the 
injected construct with HSC markers. To this end, double-stainings were performed 
for HSA and HSC-markers. As a marker for HSC, two monoclonal antibodies were 
combined: a mouse monoclonal IgG directed against desmin (Sigma) and mouse 
monoclonal IgG anti-GFAP (Neomarkers, Fremont, CA, USA) (23).  
In vitro studies with M6PHSA-DOX 
To investigate whether the in vivo binding to HSC was mediated by specific 
binding of M6PHSA-DOX to receptors on HSC, the protein backbone of the 
conjugate was labeled with 125I according to the chloramine-T method. Culture-
activated HSC were exposed to 100,000 cpm of 125I-labeled M6PHSA-DOX at 37 
°C, in the absence of a competitor for receptor binding, or in the presence of either 
1 mg/ml HSA or 1 mg/ml M6PHSA. After 2 hours, the cell-associated radioactivity 
was measured on a γ-counter (Riastar, Packard instruments, Palo Alto, USA). The 
effect of M6PHSA-DOX was investigated as described above for the uncoupled 
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drugs. The cells were incubated with 10 µg/ml M6PHSA-DOX, an equivalent 
amount of control protein, or PBS.  
Statistical analysis 
Results were expressed as the mean ± SEM. One-way ANOVA was used to 
compare means, and differences were considered statistically significant at P < 
0.05. For statistical analysis the SPSS software package was used (SPSS Inc, 










Fig. 1. Typical result of an experiment testing the effect of chlorambucil, cisplatin and 
doxorubicin on BrdU-incorporation in cultures of primary isolated, culture-activated rat HSC. Data 
are expressed as a percentage of control. 
RESULTS 
Effect of drugs on HSC proliferation in vitro 
Culture-activated rat HSC were incubated with chlorambucil, cisplatin and 
doxorubicin in various concentrations. We found that all antiproliferative drugs 
inhibited BrdU-incorporation in a dose-dependent manner (Fig. 1). Of the tested 
compounds, doxorubicin was the most potent inhibitor of HSC proliferation. In the 
concentrations used, cell morphology was not affected as assessed by phase 
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contrast microscopy (data not shown), which indicates that inhibition of 
proliferation precedes the cytotoxic effects of these drugs. 
Antifibrotic potential of doxorubicin in BDL rats 
Based on the results from the in vitro study we subsequently investigated the 
effect of DOX on the fibrotic process in vivo (Fig. 2). We found that in BDL 
animals, treatment with 0.35 mg/kg/day DOX significantly reduced the α-sma-
stained area from 8.5 ± 0.8% (PBS-treated BDL rats) to 5.1 ± 0.9% (P<0.01). In 
normal livers only 1.2 ± 0.2% of the total evaluated area of the liver was stained, 
mainly reflecting α-sma-positive vascular smooth muscle cells in the vessel walls 
(Fig. 2A-C and J). Treatment with DOX also reduced the amount of collagen, as 
reflected by a reduction in the collagen type III-stained area within liver sections to 
8.9 ± 1.5%, compared to 13.1 ± 1.3% in PBS-treated BDL animals (P<0.05). In 
livers of healthy control rats only 4.9 ± 0.5% of the area was stained for collagen 
type III (Fig 2. D-F and K). Sirius red staining confirmed the results of DOX on 
collagen deposition (Fig 2. G-I). 
Besides the antifibrotic effect of DOX, treatment with this drug also resulted in 
significant body weight loss. Furthermore, DOX treatment elicited increased serum 
γ-GT levels, but not AST and ALT levels, indicating that early hepatocyte or bile 
duct epithelial cell injury has occurred (Table 1). Yet, the absolute number of bile 
duct epithelial cells, as assessed by cytokeratin 7 staining (CK7), did not differ 
between the PBS- and DOX-treated groups (Table 1). Moreover, evaluation of 
DAB stainings revealed that the number of reactive-oxygen species-producing 
cells, was also increased in the livers of DOX-treated rats (Table 1). These DAB-
positive cells consisted mainly of neutrophils, judged by the presence of 
polymorphic nuclei in these cells after evaluation of HE-stained liver sections, and 
based on previous studies (19). 
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Fig. 2. Effect of treatment with DOX on the number of activated HSC, as assessed by α-sma 
stainings (A, B, C) and on the amount of collagen present in liver cryostat sections, as assessed by 
staining with an antibody directed against collagen III (D, E, F) or with picrosirius red (G, H, I). 
Representative microphotographs were taken at an original magnification of 40x from the livers of 
healthy animals, PBS-treated BDL-rats and DOX-treated BDL-rats. J: Quantification of α-sma 
staining by morphometric analysis. K: Quantification of collagen-III-stained area by morphometric 
analysis. Data are expressed as mean ± SEM. † indicates P < 0.01 compared to normal rats, * 





Table. 1. The effect of DOX on toxicity parameters and bile duct epithelial cell 
proliferation. * indicates P<0.05 compared to PBS-treated BDL rats. N.D: not determined. 
 
 Normal BDL 
  PBS DOX 
∆ BW 
(relative to BW at day 3) N.D. + 4.3 ± 1.0%  - 10.1 ± 1.4%* 
γ-GT (U/l)       3 ± 0  29.83 ± 4.98  75.70 ± 13.84* 
AST (U/l)     50 ± 5     310 ± 53     391 ± 37 
ALT (U/l)     30 ± 2     104 ± 32       89 ± 13 
AP (U/l)   177 ± 14     436 ± 33     398 ± 42 
inflammatory cells 
(number per microscopic field)     25 ± 1       33 ± 7       97 ± 14* 
Bile duct epithelial cells 
(% CK7-positive area per section)    0.2 ± 0.03      3.9 ± 0.5      3.3 ± 0.4 
 
Synthesis and characterization of M6PHSA-DOX  
In order to increase the HSC-specificity of DOX, a conjugate of this drug and 
M6PHSA was synthesized (Fig. 3A). Spectrophotometric analysis of the construct 
revealed that per mg of construct 66.7 µg of doxorubicin was present. Of the total 
amount of doxorubicin in the preparation only 1% was present in uncoupled form, 
as assessed by HPLC-analysis. SDS-PAGE analysis revealed that no significant 
amounts of polymeric protein could be detected in the conjugate (Fig 3B). 
Furthermore, the net negative charge of the conjugate was increased compared to 
M6PHSA and HSA, which is in agreement with molecules being covalently 
coupled to the positively-charged amine groups of HSA (Fig 3C). The retention 
times measured by anion exchange chromatography were 18.9 min, 26.5 min, and 
28.0 min for HSA, M6PHSA and M6PHSA-DOX, respectively. 
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Fig. 3. A: Schematic representation of the chemical bond between DOX and M6PHSA. B: 
Coommassie Brilliant Blue staining of an SDS-PAGE gel containing the drug carrier and the 
conjugate. Lane 1: marker, lane 2: M6PHSA-DOX, lane 3: HSA, lane 4: M6PHSA. No significant 
amount of polymeric protein could be detected. C: Elution profile of HSA, M6PHSA and M6PHSA-
DOX on a mono Q anion exchange column. Longer retention times represent an increased net 
negative charge. 
In vivo distribution of DOX and M6PHSA-DOX 
In vivo organ distribution of 125I-labeled M6PHSA-DOX 
The organ distribution of M6PHSA-DOX in rats with liver fibrosis was 























































































conjugate. In Fig. 4 it can be seen that already 50 ± 6% of the injected dose 
distributed to the liver at that time. In heart and kidney, target organs for serious 
side effects of doxorubicin, only 0.2 ± 0.1% and 1.2 ± 0.5% of the dose 
accumulated, respectively. In the different parts of the intestine less than 2% of the 
dose was found and also in the bone marrow no significant radioactivity could be 










Fig. 4. Organ distribution of radio-labeled M6PHSA-DOX. One week after ligation of the 
common bile duct, animals were injected with a tracer dose of the 125I-labeled conjugate. Animals 
were sacrificed 20 minutes after injection. Data represent the average ± SEM of 5 animals. 
Localization of the untargeted and targeted drug  
To confirm the data of organ distribution studies that were performed with 
radio-labeled M6PHSA-DOX, immunohistochemical staining for HSA was 
performed on liver sections and sections of heart and kidney, important organs with 
respect to DOX toxicity. Strong staining was found in livers in a pattern consistent 
with accumulation in the non-parenchymal cells of the liver. In hearts and kidneys, 
complete absence or only minimal staining was found, respectively (Fig. 5 A-C). 
We also investigated the actual localization of doxorubicin itself by fluorescence 
microscopy at an excitation wavelength of 450-490 nm and an emission filter > 
515 nm, at  which  DOX  fluoresces  (Fig. 5 D-I).  Administration  of  free  DOX to  










































































Fig. 5. Images of liver (A, D, G), heart (B, E, H), kidney (C, F, I) from animals receiving 
M6PHSA-DOX 30 mg/kg (upper two rows) or unconjugated DOX 2 mg/kg (lower row). 
Immunohistochemical staining for HSA (A-C) was performed to demonstrate the distribution of the 
drug carrier part of the conjugate (M6PHSA) and fluorescence microscopy was used to detect the 
drug itself (D-I). Arrows indicate the localization of DOX. Note the change in distribution of DOX 
after coupling to M6PHSA compared to the uncoupled drug. In the images J, K and L the 
autofluorescence in livers, hearts and kidneys of BDL rats is shown (original magnification 200x). M: 
Co-localization of M6PHSA-DOX with HSC-markers in the liver. The conjugate was demonstrated 
by immunohistochemical staining for HSA (red staining) and HSC were identified with anti-
desmin/GFAP antibodies (blue staining). Arrows indicate double-positive cells (original 
magnification 400x). A full color version of this figure can be found in the appendix. 
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fibrotic rats resulted in association of the drug with the nuclei of cardiomyocytes 
and with the nuclei of glomerular and tubular epithelial cells of the kidney, 20 
minutes after administration. In the livers, untargeted DOX associated with the 
nuclei of both hepatocytes and non-parenchymal cells (NPC). However, after 
coupling of DOX to M6PHSA, no DOX-specific fluorescence could be found at all 
in heart and kidney. Within the liver, drug-specific fluorescence was notable; 
animals that received M6PHSA-DOX displayed a non-parenchymal distribution 
pattern for the drug, with no detectable accumulation in hepatocytes. 
Cellular localization of M6PHSA-DOX 
To examine in which liver cells the conjugate was taken up, immuno-
histochemical double-stainings were performed on liver sections for M6PHSA-
DOX together with markers for HSC. We found that M6PHSA-DOX co-localized 
with HSC-markers (Fig. 5J). As can be seen in the same figure, cells that were 
HSA-positive but negative for HSC-markers were also found. Further investigation 
of this revealed that M6PHSA-DOX also co-localized with markers for Kupffer 
cells (ED2) and liver endothelial cells (RECA-1, data not shown).  
In vitro studies with M6PHSA-DOX 
To test whether M6PHSA-DOX selectively binds to receptors on HSC, we 
performed binding studies on culture-activated HSC with 125I-labeled M6PHSA-
DOX. In Fig. 6 it can be seen that binding to HSC was reduced by 75.2 ± 6.3% 
(P<0.05) after co-incubation with M6PHSA, which is an M6P/IGF-II receptor 
ligand. In contrast, the control protein HSA had no significant effect.  
Moreover, incubation with M6PHSA-DOX reduced HSC proliferation by 82 ± 
15% (P<0.05), whereas the drug carrier alone (M6PHSA) exerted no significant 
effect compared to vehicle-treated control cells (Fig. 7). This indicates that active 
drug is released, after binding and uptake of the conjugate by the target cells. 
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Fig. 6. The influence of competitors on the binding and uptake of 125I-labeled M6PHSA-DOX by 
culture-activated rat HSC. Note that M6PHSA, a ligand for the M6P/IGF-II receptor, reduces binding 
of the conjugate by 75.2 ± 6.5%, whereas the control protein HSA exerts no significant effect. Data 
represent the average ± SEM of 3 independent experiments from 3 different HSC isolations. * 









Fig. 7.  Effect of M6PHSA and M6PHSA-DOX on HSC proliferation in vitro. * indicates P<0.05 
compared to control. Data represent the average ± SEM of 3 independent experiments from 3 
different HSC isolations. 
DISCUSSION 
In the present paper we show that DOX is a potent inhibitor of HSC 
proliferation in vitro, inhibiting cellular proliferation in the nanomolar 
concentration range. This is in lower concentrations than a number of other typical 
inhibitors of HSC proliferation in vitro, such as mycophenolic acid, statins, the 
Chapter 5 
102 
selective Na+/H+ exchange inhibitor cariporide and the semi-synthetic analogue of 
fumagillin TNP-470 (4;18;24;25). The higher potency of DOX may be related to 
the fact that multiple intracellular mechanisms are implicated in its antiproliferative 
effect, in contrast to these other drugs (26). In this paper we also show that 
treatment of bile duct ligated rats with doxorubicin reduces the number of activated 
HSC in the fibrotic rat liver and attenuates the fibrotic process. To our knowledge, 
this is the first study investigating the use of a cytostatic agent in an experimental 
model of liver fibrosis and our data indicate that DOX in principle may form a new 
asset in the treatment of liver fibrosis, for which up till now no 
pharmacotherapeutics are available. However, the observed side effects will most 
certainly impede its actual clinical application. In fact, toxicity is a typical problem 
that forms an obstacle in the application of many other promising antifibrotic drugs 
as well (27-30). 
In this study, the toxicity of DOX was reflected by the loss in body weight, 
whereas the increased in serum γ-GT levels, but not AST, ALT and AP levels, also 
suggested hepatocyte or bile duct epithelial cell injury. It is known that during the 
early stages of hepatocellular injury such an isolated γ-GT increase can precede 
AP, ALT or AST elevation (31). Very likely, the increased number of DAB-
positive cells that we observed is the result of an immune response in reaction to 
this damage. It is known that drug-induced hepatic inflammation can lead to liver 
fibrosis, but usually this takes a prolonged period of time. In the present animal 
model, which is characterized by a very fast proliferation of fibrogenic cells, the 
antiproliferative effect of DOX on these cells apparently prevails, resulting in the 
observed antifibrotic effect. It would therefore be interesting to investigate the 
antifibrotic potential of DOX in animal models in which fibrosis progression is 
slower, for example in the CCl4 model. In this BDL model, the antifibrogenic 
effect of DOX was most prominent in the parenchyma and less clear in the portal 
areas. Whether this is due to a reduced sensitivity of portal fibroblasts to DOX, or  
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due to lower drug concentrations in this highly fibrotic area, remains to be 
established. 
Although this DOX-induced hepatic inflammation does not result in a 
worsening of fibrosis, it should still be considered that an even more potent 
antifibrotic effect can be obtained, when the influx of inflammatory cells is 
avoided. The same may be true for the observed weight loss seen in DOX-treated 
rats, since it has been shown that alcohol in combination with malnutrition causes 
more severe liver fibrosis in rats (32). In this way HSC-selective delivery of DOX 
may not only help to avoid general drug-related toxicity, but also contribute to the 
antifibrogenic potential of DOX via the avoidance of pro-fibrogenic side effects.  
Analysis of circulating white blood cell counts revealed no significant 
differences between DOX-treated BDL rats and PBS-treated BDL rats (data not 
shown), suggesting that no relevant meyelosuppressive effect was at hand at the 
present dose of DOX and duration of administration. This renders it unlikely that 
the antifibrotic effect of DOX we describe here is mediated via the known 
meyelosuppressive effect of the drug. 
Besides the proliferation of HSC, proliferation of ductular epithelial cells 
occurs in the liver after ligation of the common bile duct. Our data revealed that the 
ductular response of BDL rats was not significantly affected by treatment with 
DOX. A possible reason for this is the high expression of mdr1a drug efflux 
transporters in the apical membrane of the cholangiocytes (33). Since doxorubicin 
is a substrate for mdr1a, it is conceivable that the resistance of cholangiocytes to 
DOX is due to a high efflux of the drug from these cells. 
To limit the effect of DOX to fibrogenic cells and to avoid the described extra- 
and intrahepatic toxicity, we set out to investigate the targeted delivery of DOX to 
the HSC. From physico-chemical analyses we concluded that coupling of DOX to 
the HSC-selective drug carrier M6PHSA was successful. In vivo, the conjugate 
rapidly and selectively accumulated in the liver, whereas the untargeted drug also 
accumulated in organs that are prone to DOX toxicity. Within the liver, the uptake 
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of M6PHSA-DOX was confined to the non-parenchymal cells and the observed co-
localization of M6PHSA-DOX with HSC-markers indicated that HSC were 
reached successfully. Next to the uptake in HSC, also co-localization with Kupffer 
cell and endothelial cell markers was observed. This very likely reflects scavenger 
receptor-mediated uptake of M6PHSA-DOX by these cells, since this is a highly 
negatively charged molecule. To attenuate uptake by these other non-parenchymal 
cells, the net charge of this construct should be modified. Nevertheless, we could 
clearly demonstrate that, although not 100% specific, injection with M6PHSA-
DOX leads to a significant increase in stellate cell-selectivity compared to the 
untargeted drug. It remains to be established if the uptake of M6PHSA-DOX in 
Kupffer cells and liver endothelial cells results in toxicity or whether this 
contributes to the therapeutic effect of the conjugate. It is known from literature 
that an attenuation of Kupffer cell functioning may attenuate fibrogenesis (34). 
The binding of M6PHSA-DOX to HSC was confirmed by studies performed 
with a 125I-labeled conjugate in cultures of activated HSC. The association of radio-
labeled M6PHSA-DOX with the cells could be inhibited by an excess of M6PHSA 
but not by HSA, indicating that receptor-mediated uptake of the construct takes 
place. Moreover, the strong inhibition of cell proliferation by M6PHSA-DOX that 
we observed also indicates that active drug can be released from the conjugate after 
uptake by activated HSC.  
Although these results show that the targeted delivery of a cytostatic drug to 
the HSC is possible, it is evident that chronic treatment of fibrotic rats is necessary 
to test the ultimate antifibrotic potential of this targeted strategy. However, before 
performing those studies, it will be necessary to better understand the 
pharmacokinetics of M6PHSA-DOX in fibrotic animals, as well as its intracellular 
kinetics within HSC. Explicitly, information on the mechanisms through which this 
new chemical entity is processed by activated HSC, and the rate at which 
intracellular drug release and elimination occur, will largely dictate the dosage 
regime of M6PHSA-DOX in chronically treated rats. Based on the expected 
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differences in cellular handling between the targeted and untargeted drug, this may 
be very dissimilar for the two compounds. Yet, irrespective of the eventual dosing 
regimen required, it is likely that by virtue of the improved organ and cell 
specificity, and the resulting smaller volume of distribution, the total body dose of 
M6PHSA-DOX can be reduced compared to untargeted DOX, whereas still similar 
drug concentrations can be obtained within HSC. 
In summary, we have shown that treatment of BDL rats with free DOX inhibits 
the progression of experimental liver fibrosis and strongly inhibits HSC 
proliferation in vitro. Subsequently, we succeeded in delivering this potent 
antiproliferative drug to HSC in vitro as well as in vivo. By doing so, accumulation 
of DOX in extrahepatic tissues as well as hepatocytes was avoided. We conclude 
that DOX exerts potent antifibrotic effects in bile duct-ligated rats. In conjunction 
with the here-described drug delivery strategy this may offer perspectives for the 
use of potent but relatively toxic antiproliferative drugs in the pharmacological 
treatment of liver fibrosis. 
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